Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2009 2
2010 2
2014 7
2015 6
2016 4
2017 2
2018 9
2019 16
2020 12
2021 8
2022 18
2023 14
2024 19
2025 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

119 results

Results by year

Filters applied: . Clear all
Page 1
Siglec receptors as new immune checkpoints in cancer.
Stanczak MA, Läubli H. Stanczak MA, et al. Among authors: laubli h. Mol Aspects Med. 2023 Apr;90:101112. doi: 10.1016/j.mam.2022.101112. Epub 2022 Aug 7. Mol Aspects Med. 2023. PMID: 35948467 Free article. Review.
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.
Melero I, de Miguel Luken M, de Velasco G, Garralda E, Martín-Liberal J, Joerger M, Alonso G, Goebeler ME, Schuler M, König D, Dummer R, Reig M, Rodriguez Ruiz ME, Calvo E, Esteban-Villarrubia J, Oberoi A, Sabat P, Soto-Castillo JJ, Koster KL, Saavedra O, Sayehli C, Gromke T, Läubli H, Ramelyte E, Fortuny M, Landa-Magdalena A, Moreno I, Torres-Jiménez J, Hernando-Calvo A, Hess D, Racca F, Richly H, Schmitt AM, Eggenschwiler C, Sanduzzi-Zamparelli M, Vilalta-Lacarra A, Trojan J, Koch C, Galle PR, Foerster F, Trajanoski Z, Hackl H, Gogolla F, Koll FJ, Wild P, Chun FKH, Reis H, Lloyd P, Machacek M, Gajewski TF, Fridman WH, Eggermont AMM, Bargou R, Schöniger S, Rüschoff J, Tereshchenko A, Zink C, da Silva A, Lichtenegger FS, Akdemir J, Rüdiger M, L'Huillier P, Dutta A, Haake M, Auckenthaler A, Gjorgjioska A, Rössler B, Hermann F, Liebig M, Reichhardt D, Schuberth-Wagner C, Wischhusen J, Fettes P, Auer M, Klar K, Leo E. Melero I, et al. Among authors: laubli h. Nature. 2025 Jan;637(8048):1218-1227. doi: 10.1038/s41586-024-08305-z. Epub 2024 Dec 11. Nature. 2025. PMID: 39663448 Free PMC article. Clinical Trial.
Targeted glycan degradation potentiates the anticancer immune response in vivo.
Gray MA, Stanczak MA, Mantuano NR, Xiao H, Pijnenborg JFA, Malaker SA, Miller CL, Weidenbacher PA, Tanzo JT, Ahn G, Woods EC, Läubli H, Bertozzi CR. Gray MA, et al. Among authors: laubli h. Nat Chem Biol. 2020 Dec;16(12):1376-1384. doi: 10.1038/s41589-020-0622-x. Epub 2020 Aug 17. Nat Chem Biol. 2020. PMID: 32807964 Free PMC article.
Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade.
Stanczak MA, Rodrigues Mantuano N, Kirchhammer N, Sanin DE, Jacob F, Coelho R, Everest-Dass AV, Wang J, Trefny MP, Monaco G, Bärenwaldt A, Gray MA, Petrone A, Kashyap AS, Glatz K, Kasenda B, Normington K, Broderick J, Peng L, Pearce OMT, Pearce EL, Bertozzi CR, Zippelius A, Läubli H. Stanczak MA, et al. Among authors: laubli h. Sci Transl Med. 2022 Nov 2;14(669):eabj1270. doi: 10.1126/scitranslmed.abj1270. Epub 2022 Nov 2. Sci Transl Med. 2022. PMID: 36322632 Free PMC article.
Cancer Immunotherapy.
Pearce OMT, Läubli H. Pearce OMT, et al. Among authors: laubli h. Glycobiology. 2018 Sep 1;28(9):638-639. doi: 10.1093/glycob/cwy069. Glycobiology. 2018. PMID: 30084981 No abstract available.
Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy.
Trefny MP, Kirchhammer N, Auf der Maur P, Natoli M, Schmid D, Germann M, Fernandez Rodriguez L, Herzig P, Lötscher J, Akrami M, Stinchcombe JC, Stanczak MA, Zingg A, Buchi M, Roux J, Marone R, Don L, Lardinois D, Wiese M, Jeker LT, Bentires-Alj M, Rossy J, Thommen DS, Griffiths GM, Läubli H, Hess C, Zippelius A. Trefny MP, et al. Among authors: laubli h. Nat Commun. 2023 Feb 2;14(1):86. doi: 10.1038/s41467-022-35583-w. Nat Commun. 2023. PMID: 36732507 Free PMC article.
Targeting the Siglec-sialic acid axis promotes antitumor immune responses in preclinical models of glioblastoma.
Schmassmann P, Roux J, Buck A, Tatari N, Hogan S, Wang J, Rodrigues Mantuano N, Wieboldt R, Lee S, Snijder B, Kaymak D, Martins TA, Ritz MF, Shekarian T, McDaid M, Weller M, Weiss T, Läubli H, Hutter G. Schmassmann P, et al. Among authors: laubli h. Sci Transl Med. 2023 Jul 19;15(705):eadf5302. doi: 10.1126/scitranslmed.adf5302. Epub 2023 Jul 19. Sci Transl Med. 2023. PMID: 37467314
High-throughput T cell receptor engineering by functional screening identifies candidates with enhanced potency and specificity.
Vazquez-Lombardi R, Jung JS, Schlatter FS, Mei A, Mantuano NR, Bieberich F, Hong KL, Kucharczyk J, Kapetanovic E, Aznauryan E, Weber CR, Zippelius A, Läubli H, Reddy ST. Vazquez-Lombardi R, et al. Among authors: laubli h. Immunity. 2022 Oct 11;55(10):1953-1966.e10. doi: 10.1016/j.immuni.2022.09.004. Epub 2022 Sep 28. Immunity. 2022. PMID: 36174557 Free article.
Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker.
Martins TA, Kaymak D, Tatari N, Gerster F, Hogan S, Ritz MF, Sabatino V, Wieboldt R, Bartoszek EM, McDaid M, Gerber A, Buck A, Beshirova A, Heider A, Shekarian T, Mohamed H, Etter MM, Schmassmann P, Abel I, Boulay JL, Saito Y, Mariani L, Guzman R, Snijder B, Weiss T, Läubli H, Hutter G. Martins TA, et al. Among authors: laubli h. Nat Commun. 2024 Nov 9;15(1):9718. doi: 10.1038/s41467-024-54129-w. Nat Commun. 2024. PMID: 39521782 Free PMC article.
119 results